Dossier
Awiqli
Coverage of Awiqli in the Nexus archive.
Baxfendytopic2Veppanutopic2CVS Healthorganization1Eli Lillyorganization1Zepboundtopic1Foundayotopic1Trump's most-favored-nation dealstopic1AstraZenecaorganization1Novo Nordiskorganization1Arvinasorganization1Pfizerorganization1Rigel Pharmaceuticalsorganization1Trumpperson1most-favored-nation dealstopic1
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
President Trump's most-favored-nation drug pricing deals with 17 drugmakers will be tested by three new prescription drugs set to launch soon. The drugs, Baxfendy (hypertension), Awiqli (insulin), and Veppanu (cancer), will offer the first public insight into the practical impacts of these secretive pricing agreements.